R01EB033155
Project Grant
Overview
Grant Description
LASER PARTICLES FOR MULTI-DIMENSIONAL SINGLE-CELL ANALYSIS - Project Summary
The broad objective of this proposed work is to advance single-cell analysis by introducing novel cell-barcoding technologies. Understanding cells is a cornerstone of life sciences. Single-cell sequencing led to a paradigm shift in our approach to analyze cells from ensembles to individual cells. Unfortunately, the current single-cell analysis techniques are almost exclusively static, performed ex vivo, and thus cannot easily probe the dynamic cellular processes.
Beyond static analysis, the next important step is to add more dimensions: everything that makes a cell a living entity, including temporal changes, spatial movement, interactions with other cells in vivo. This project will develop Laser Particles (LPs), which can be read optically in real time and repeatedly as needed, for multi-dimensional single-cell analysis. With the optical barcode, it is possible to acquire data from a cell at different times, locations, and apparatuses, and compile the data to produce a full account of the cell.
A combination of LPs with oligonucleotide barcodes enables a breakthrough approach acquiring large-scale data from in vivo physiology to molecular omics using multiple instruments in series. This project is organized in three specific aims.
Aim 1 develops large-scale LP barcodes combined with oligo barcodes.
Aim 2 constructs several instruments integrating LP barcode readers into commercial platforms.
Aim 3 involves validation studies to demonstrate the immediate utilities of the new technologies.
The optical barcoding is expected to make a paradigm change in single-cell analysis. This will transform the way multi-dimensional single-cell analysis is used for scientific discovery and diagnostic and therapeutic applications in healthcare.
The broad objective of this proposed work is to advance single-cell analysis by introducing novel cell-barcoding technologies. Understanding cells is a cornerstone of life sciences. Single-cell sequencing led to a paradigm shift in our approach to analyze cells from ensembles to individual cells. Unfortunately, the current single-cell analysis techniques are almost exclusively static, performed ex vivo, and thus cannot easily probe the dynamic cellular processes.
Beyond static analysis, the next important step is to add more dimensions: everything that makes a cell a living entity, including temporal changes, spatial movement, interactions with other cells in vivo. This project will develop Laser Particles (LPs), which can be read optically in real time and repeatedly as needed, for multi-dimensional single-cell analysis. With the optical barcode, it is possible to acquire data from a cell at different times, locations, and apparatuses, and compile the data to produce a full account of the cell.
A combination of LPs with oligonucleotide barcodes enables a breakthrough approach acquiring large-scale data from in vivo physiology to molecular omics using multiple instruments in series. This project is organized in three specific aims.
Aim 1 develops large-scale LP barcodes combined with oligo barcodes.
Aim 2 constructs several instruments integrating LP barcode readers into commercial platforms.
Aim 3 involves validation studies to demonstrate the immediate utilities of the new technologies.
The optical barcoding is expected to make a paradigm change in single-cell analysis. This will transform the way multi-dimensional single-cell analysis is used for scientific discovery and diagnostic and therapeutic applications in healthcare.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Place of Performance
Cambridge,
Massachusetts
021394232
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 376% from $735,306 to $3,502,889.
The General Hospital Corporation was awarded
Laser Particles for Single-Cell Analysis
Project Grant R01EB033155
worth $3,502,889
from the National Institute of Allergy and Infectious Diseases in September 2021 with work to be completed primarily in Cambridge Massachusetts United States.
The grant
has a duration of 4 years 9 months and
was awarded through assistance program 93.310 Trans-NIH Research Support.
The Project Grant was awarded through grant opportunity NIH Directors Transformative Research Awards (R01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 6/20/25
Period of Performance
9/30/21
Start Date
6/30/26
End Date
Funding Split
$3.5M
Federal Obligation
$0.0
Non-Federal Obligation
$3.5M
Total Obligated
Activity Timeline
Transaction History
Modifications to R01EB033155
Additional Detail
Award ID FAIN
R01EB033155
SAI Number
R01EB033155-1111222460
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75N800 NIH National Institute of Biomedical Imaging and Bioengineering
Funding Office
75NA00 NIH OFFICE OF THE DIRECTOR
Awardee UEI
FLJ7DQKLL226
Awardee CAGE
0ULU5
Performance District
MA-07
Senators
Edward Markey
Elizabeth Warren
Elizabeth Warren
Budget Funding
| Federal Account | Budget Subfunction | Object Class | Total | Percentage |
|---|---|---|---|---|
| Office of the Director, National Institutes of Health, Health and Human Services (075-0846) | Health research and training | Grants, subsidies, and contributions (41.0) | $1,474,951 | 100% |
Modified: 6/20/25